Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis

AJ Muir; F Poordad; J Lalezari; G Everson; GJ Dore; R Herring; A Sheikh; P Kwo; C Hézode; PJ Pockros; A Tran; J Yozviak; N Reau; A Ramji; K Stuart; AJ Thompson; J Vierling; B Freilich; J Cooper; W Ghesquiere; R Yang; F McPhee; EA Hughes; ES Swenson; PD Yin

Journal article

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis

AJ Muir, F Poordad, J Lalezari, G Everson, GJ Dore, R Herring, A Sheikh, P Kwo, C Hézode, PJ Pockros, A Tran, J Yozviak, N Reau, A Ramji, K Stuart, AJ Thompson, J Vierling, B Freilich, J Cooper, W Ghesquiere Show all

JAMA Journal of the American Medical Association | Published : 2015

DOI: 10.1001/jama.2015.3868

Abstract

IMPORTANCE: Effective and well-tolerated, interferon-free regimens are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis. OBJECTIVE: All-oral therapy with daclatasvir (nonstructural protein 5A [NS5A] inhibitor), asunaprevir (NS3 protease inhibitor), and beclabuvir (nonnucleoside NS5B inhibitor), with or without ribavirin, was evaluated in patients with HCV genotype 1 infection and compensated cirrhosis. DESIGN, SETTING, AND PARTICIPANTS: The UNITY-2 study was conducted between December 2013 and October 2014 at 49 outpatient sites in the United States, Canada, France, and Australia. Patients were treated for 12 weeks, with 24 weeks of follow-up afte..

View full abstract